Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 9/20 | 0.62 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.57 |
| ▸ | TUBB | P07437 | 1/20 | 0.57 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.57 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.57 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.57 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.57 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.57 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.57 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.57 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.57 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.57 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.57 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.57 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.57 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.57 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.56 |
| ▸ | GLP1R | P43220 | 3/20 | 0.55 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.55 |
| ▸ | GCGR | P47871 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29883587 | 0.95 | IL23R (0.61) | IL23RTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29540806 | 0.94 | IL23R (0.60) | IL23RTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29613381 | 0.93 | GLP1R (0.61) | IL23RGLP1RGCGR | |
| SCHEMBL29965711 | 0.92 | CXCR4 (0.56) | IL23RTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29641105 | 0.90 | IL23R (0.57) | IL23RTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29641071 | 0.90 | IL23R (0.57) | IL23RTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL30463394 | 0.89 | IL23R (0.57) | IL23RTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29672885 | 0.89 | IL23R (0.57) | IL23RTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL30132314 | 0.88 | TUBB4A (0.57) | IL23RTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29641170 | 0.88 | TUBB4A (0.57) | IL23RTUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4711005-A2 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | Stealth BioTherapeutics Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TUFTS MEDICAL CENTER, INC. | 2025-09-04 | — | — | US | disclosed |
| US-20250263433-A1 | METHODS FOR REDUCING CD36 EXPRESSION | CORNELL RESEARCH FOUNDATION, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250255929-A1 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-08-14 | — | — | US | disclosed |
| EP-4596049-A2 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250161401-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4302829-B1 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | STEALTH BIOTHERAPEUTICS INC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-3603658-B1 | PEPTIDE FOR USE IN THE TREATMENT OF HEART FAILURE RESULTING FROM HYPERTROPHIC CARDIOMYOPATHY | UNIV CORNELL (US) | 2025-01-08 | — | — | EP | disclosed |
| US-12102659-B2 | Methods for the prevention or treatment of heart failure | CORNELL UNIVERSITY (US) | 2024-10-01 | — | — | US | disclosed |
| EP-4397314-A1 | TREATMENT OF LEFT VENTRICULAR REMODELING | Stealth BioTherapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-3890765-B1 | D-ARG-2'6'-DMT-LYS-PHE-NH2 FOR USE IN TREATING OR PREVENTING SENGERS SYNDROME | STEALTH BIOTHERAPEUTICS INC (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230285499-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE | CORNELL UNIVERSITY (US) | 2023-09-14 | — | — | US | disclosed |
| EP-4233887-A1 | METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Stealth BioTherapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230149501-A1 | METHODS FOR REDUCING OXIDATIVE DAMAGE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230109564-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-04-06 | — | — | US | disclosed |
| EP-3513800-B1 | AROMATIC-CATIONIC PEPTIDE FOR USE IN THE TREATMENT OF ANTIPHOSPHOLIPID SYNDROME | UNIV CORNELL (US) | 2022-12-07 | — | — | EP | disclosed |
| US-11376304-B2 | Methods and compositions for the prevention and treatment of disease | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11366104-B2 | Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-06-21 | — | — | US | disclosed |
| EP-4005582-A1 | TREATMENT OF LEFT VENTRICULAR REMODELING | Stealth BioTherapeutics Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-4000690-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | Stealth BioTherapeutics Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285499-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE | TNNI3, FABP3, TNNC1 | IL23R 4061/4885TUBB4A 2209/4885TUBB 1353/4885 |
| US-20250255929-A1 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | TNNI3, TNNT2, FABP3 | IL23R 2859/4885TUBB4A 1499/4885TUBB 1100/4885 |
| US-20250161401-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | MTPN, UTRN, SMN1; SMN2 | IL23R 4208/4885TUBB4A 3495/4885TUBB 2762/4885 |
| US-12102659-B2 | Methods for the prevention or treatment of heart failure | TNNI3, FABP3, TNNC1 | IL23R 4061/4885TUBB4A 2209/4885TUBB 1353/4885 |
| US-20230109564-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | MTPN, UTRN, SMN1; SMN2 | IL23R 4208/4885TUBB4A 3495/4885TUBB 2762/4885 |
| US-11376304-B2 | Methods and compositions for the prevention and treatment of disease | COL2A1, ALPI, COL14A1 | IL23R 1209/4885TUBB4A 487/4885TUBB 1461/4885 |
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TNNI3, TNNT2, MB | IL23R 4785/4885TUBB4A 2163/4885TUBB 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.